pyrazinamide has been researched along with Disease Exacerbation in 16 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tuberculosis was associated with an increased mortality (adjusted rate ratio 1." | 2.70 | Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. ( Fuchs, D; Godfrey-Faussett, P; Hosp, M; Lisse, I; Mwinga, A; Quigley, MA, 2001) |
| " Stochastic PK/pharmacodynamic (PD) simulations were carried out to evaluate current regimen combinations and dosing guidelines in distinct patient strata." | 1.51 | Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization. ( Bang, H; Barry, CE; Dartois, V; Eum, S; Fox, WS; Gupta, SV; Lee, M; Savic, RM; Shim, T; Strydom, N; Via, LE; Zimmerman, M, 2019) |
| "When active tuberculosis is identified, combination therapy with isoniazid, rifampin, pyrazinamide, and ethambutol should be promptly initiated for a two-month "intensive phase," and in most cases, followed by isoniazid and a rifamycin product for a four- to seven-month "continuation phase." | 1.35 | Update on the treatment of tuberculosis. ( Inge, LD; Wilson, JW, 2008) |
| "No other case of spondylodiscitis caused by a mycobacterial coinfection pathogen has been reported so far." | 1.33 | [Cervical spondylodiscitis: one pathogen may hide another]. ( Ader, F; Bernard, L; Carlier, R; Perronne, C; Salomon, J; Toubiana, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 10 (62.50) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marks, SM | 1 |
| Mase, SR | 1 |
| Morris, SB | 1 |
| Soto-Cabrera, E | 1 |
| Villamil-Osorio, LV | 1 |
| Garcia-Luna, RC | 1 |
| Carrera-Pineda, R | 1 |
| Strydom, N | 1 |
| Gupta, SV | 1 |
| Fox, WS | 1 |
| Via, LE | 1 |
| Bang, H | 1 |
| Lee, M | 1 |
| Eum, S | 1 |
| Shim, T | 1 |
| Barry, CE | 1 |
| Zimmerman, M | 1 |
| Dartois, V | 1 |
| Savic, RM | 1 |
| Boerrigter, BG | 1 |
| van Sandwijk, MS | 1 |
| van den Berk, GE | 1 |
| Padmavathy, L | 1 |
| Rao, LL | 1 |
| Ethirajan, N | 1 |
| Dhanlaklshmi, M | 1 |
| Inge, LD | 1 |
| Wilson, JW | 1 |
| Skvortsova, LA | 1 |
| Pavlova, MV | 1 |
| Kondakova, MN | 1 |
| Vinogradova, TI | 1 |
| Kovaleva, RG | 1 |
| Archakova, LI | 1 |
| Duarte, R | 1 |
| Carvalho, A | 1 |
| Correia, A | 1 |
| Long, R | 1 |
| Bochar, K | 1 |
| Chomyc, S | 1 |
| Talbot, J | 1 |
| Barrie, J | 1 |
| Kunimoto, D | 1 |
| Tilley, P | 1 |
| Frisch, IB | 1 |
| Kunze, AK | 1 |
| Castro, A | 1 |
| Krastel, H | 1 |
| Meinck, HM | 1 |
| Chacko, AG | 1 |
| Moorthy, RK | 1 |
| Chandy, MJ | 1 |
| Toubiana, J | 1 |
| Salomon, J | 1 |
| Ader, F | 1 |
| Perronne, C | 1 |
| Carlier, R | 1 |
| Bernard, L | 1 |
| Schechter, M | 1 |
| Zajdenverg, R | 1 |
| Falco, G | 1 |
| Barnes, GL | 1 |
| Faulhaber, JC | 1 |
| Coberly, JS | 1 |
| Moore, RD | 1 |
| Chaisson, RE | 1 |
| Asano, T | 1 |
| Kawamoto, H | 1 |
| Asakuma, J | 1 |
| Tanimoto, T | 1 |
| Kobayashi, H | 1 |
| Hayakawa, M | 1 |
| Quigley, MA | 1 |
| Mwinga, A | 1 |
| Hosp, M | 1 |
| Lisse, I | 1 |
| Fuchs, D | 1 |
| Godfrey-Faussett, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery[NCT00816426] | Phase 1 | 19 participants (Actual) | Interventional | 2008-12-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pyrazinamide and Disease Exacerbation
| Article | Year |
|---|---|
Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Disease Progression; Drug Resistance, Multiple, Bacter | 2017 |
2 trials available for pyrazinamide and Disease Exacerbation
| Article | Year |
|---|---|
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
Topics: Adult; Antitubercular Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combi | 2006 |
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Cohort St | 2001 |
13 other studies available for pyrazinamide and Disease Exacerbation
| Article | Year |
|---|---|
[Optochiasmatic tuberculomas as a paradoxical reaction to treatment for meningeal tuberculosis].
Topics: Adult; Antitubercular Agents; Brain Infarction; Diagnostic Errors; Disease Progression; Drug Resista | 2018 |
Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
Topics: Adult; Antitubercular Agents; Decision Support Techniques; Disease Progression; Drug Administration | 2019 |
A breathtaking response to tuberculosis therapy.
Topics: Adult; Antitubercular Agents; Disease Progression; Dyspnea; Ethambutol; Female; Humans; Isoniazid; M | 2013 |
Psoriasiform lupus vulgaris.
Topics: Adolescent; Antitubercular Agents; Biopsy; Buttocks; Child; Disease Progression; Ethambutol; Female; | 2008 |
Update on the treatment of tuberculosis.
Topics: Antitubercular Agents; Comorbidity; Directly Observed Therapy; Disease Progression; Drug Therapy, Co | 2008 |
[A role of the HLA-DRB1* genotype in the complex therapy of pulmonary tuberculosis].
Topics: Alleles; Antibiotics, Antitubercular; Antitubercular Agents; Disease Progression; Drug Resistance, B | 2008 |
Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female | 2012 |
Relative versus absolute noncontagiousness of respiratory tuberculosis on treatment.
Topics: Academic Medical Centers; Adult; Alberta; Antibiotics, Antitubercular; Antitubercular Agents; Colony | 2003 |
[Severe course and contingent risk factors in optic neuropathy and myelopathy after tuberculostatics].
Topics: Adult; Antitubercular Agents; Disease Progression; Drug Therapy, Combination; Ethambutol; Humans; Is | 2003 |
The transpedicular approach in the management of thoracic spine tuberculosis: a short-term follow up study.
Topics: Abscess; Adolescent; Adult; Aged; Antitubercular Agents; Braces; Combined Modality Therapy; Curettag | 2004 |
[Cervical spondylodiscitis: one pathogen may hide another].
Topics: Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Cervical Vertebrae; Cholecystitis; Disc | 2006 |
Paradoxical worsening of tuberculosis after anti-TB therapy in a kidney transplant recipient.
Topics: Adult; Antitubercular Agents; Disease Progression; Drug Therapy, Combination; Ethambutol; Female; Hu | 2000 |
New TB therapy works for HIV-positive patients.
Topics: Antitubercular Agents; Clinical Trials as Topic; Disease Progression; HIV Infections; Humans; Isonia | 1998 |